TY - JOUR
T1 - Evasion of the p53 tumour surveillance network by tumour-derived MYC mutants
AU - Hemann, Michael T
AU - Bric, Anka
AU - Teruya-Feldstein, Julie
AU - Herbst, Andreas
AU - Nilsson, Jonas A
AU - Cordon-Cardo, Carlos
AU - Cleveland, John L
AU - Tansey, William P
AU - Lowe, Scott W
PY - 2005/8/11
Y1 - 2005/8/11
N2 - The c-Myc oncoprotein promotes proliferation and apoptosis, such that mutations that disable apoptotic programmes often cooperate with MYC during tumorigenesis. Here we report that two common mutant MYC alleles derived from human Burkitt's lymphoma uncouple proliferation from apoptosis and, as a result, are more effective than wild-type MYC at promoting B cell lymphomagenesis in mice. Mutant MYC proteins retain their ability to stimulate proliferation and activate p53, but are defective at promoting apoptosis due to a failure to induce the BH3-only protein Bim (a member of the B cell lymphoma 2 (Bcl2) family) and effectively inhibit Bcl2. Disruption of apoptosis through enforced expression of Bcl2, or loss of either Bim or p53 function, enables wild-type MYC to produce lymphomas as efficiently as mutant MYC. These data show how parallel apoptotic pathways act together to suppress MYC-induced transformation, and how mutant MYC proteins, by selectively disabling a p53-independent pathway, enable tumour cells to evade p53 action during lymphomagenesis.
AB - The c-Myc oncoprotein promotes proliferation and apoptosis, such that mutations that disable apoptotic programmes often cooperate with MYC during tumorigenesis. Here we report that two common mutant MYC alleles derived from human Burkitt's lymphoma uncouple proliferation from apoptosis and, as a result, are more effective than wild-type MYC at promoting B cell lymphomagenesis in mice. Mutant MYC proteins retain their ability to stimulate proliferation and activate p53, but are defective at promoting apoptosis due to a failure to induce the BH3-only protein Bim (a member of the B cell lymphoma 2 (Bcl2) family) and effectively inhibit Bcl2. Disruption of apoptosis through enforced expression of Bcl2, or loss of either Bim or p53 function, enables wild-type MYC to produce lymphomas as efficiently as mutant MYC. These data show how parallel apoptotic pathways act together to suppress MYC-induced transformation, and how mutant MYC proteins, by selectively disabling a p53-independent pathway, enable tumour cells to evade p53 action during lymphomagenesis.
KW - Adoptive Transfer
KW - Alleles
KW - Animals
KW - Apoptosis
KW - Apoptosis Regulatory Proteins
KW - Bcl-2-Like Protein 11
KW - Burkitt Lymphoma/genetics
KW - Carrier Proteins/metabolism
KW - Cell Cycle Proteins/metabolism
KW - Cell Proliferation
KW - Cyclin-Dependent Kinase Inhibitor p16
KW - Cyclin-Dependent Kinase Inhibitor p21
KW - Genes, myc/genetics
KW - Humans
KW - Membrane Proteins/metabolism
KW - Mice
KW - Mice, Inbred C57BL
KW - Mutation/genetics
KW - Proto-Oncogene Proteins/metabolism
KW - Proto-Oncogene Proteins c-bcl-2/metabolism
KW - Proto-Oncogene Proteins c-myc/genetics
KW - Stem Cell Transplantation
KW - Tumor Suppressor Protein p14ARF/metabolism
KW - Tumor Suppressor Protein p53/metabolism
U2 - 10.1038/nature03845
DO - 10.1038/nature03845
M3 - Article
C2 - 16094360
SN - 0028-0836
VL - 436
SP - 807
EP - 811
JO - Nature
JF - Nature
IS - 7052
ER -